Acrivon Therapeutics earnings were -$80.6M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest ACRV earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$22.8M, up 1.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ACRV reported annual earnings of -$80.6M, with 33.4% growth.
Acrivon Therapeutics Earnings Reports & History FAQ
What were Acrivon Therapeutics's earnings last quarter?
Acrivon Therapeutics (NASDAQ: ACRV) reported Q4 2024 earnings per share (EPS) of -$0.59, up 32.18% year over year. Total ACRV earnings for the quarter were -$22.83 million. In the same quarter last year, Acrivon Therapeutics's earnings per share (EPS) was -$0.87.
Is Acrivon Therapeutics profitable or losing money?
As of the last Acrivon Therapeutics earnings report, Acrivon Therapeutics is currently losing money. Acrivon Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$80.56 million, a 33.4% increase year over year.
What was ACRV's earnings growth in the past year?
As of Acrivon Therapeutics's earnings date in Q2 2025, Acrivon Therapeutics's earnings has grown year over year. ACRV earnings in the past year totalled -$80.56 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.